Xanthatin anti-tumor cytotoxicity is mediated via glycogen synthase kinase-3β and β-catenin

Biochem Pharmacol. 2016 Sep 1:115:18-27. doi: 10.1016/j.bcp.2016.06.009. Epub 2016 Jun 16.

Abstract

Xanthatin, a xanthanolide sesquiterpene lactone isolated from Xanthium strumarium L. (Asteraceae), has prominent anti-tumor activity. Initial mechanism of action studies suggested xanthatin triggered activation of Wnt/β-catenin. We examined the effects of xanthatin on signaling pathways in A459 lung cancer cells and mouse embryonic fibroblasts to ascertain requirements for xanthatin-induced cell death and tumor growth in xenografts. Genetic inactivation of GSK-3β, but not the related isoform GSK-3α, compromised xanthatin cytotoxicity while inactivation of β-catenin enhanced xanthatin-mediated cell death. These data provide insight into how xanthatin and related molecules could be effectively targeted toward certain tumors.

Keywords: GSK-3; Natural compound; Tumor growth; Xanthatin; β-Catenin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents, Phytogenic / pharmacology*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Cell Line, Tumor
  • Furans / pharmacology*
  • Glycogen Synthase Kinase 3 beta / metabolism*
  • Humans
  • Lung Neoplasms / drug therapy*
  • Mice
  • Phosphorylation
  • Signal Transduction / drug effects
  • Tumor Cells, Cultured
  • Xanthium / chemistry
  • beta Catenin / metabolism*

Substances

  • Antineoplastic Agents, Phytogenic
  • Furans
  • beta Catenin
  • xanthatin
  • Glycogen Synthase Kinase 3 beta